| 前收盘价格 | 19.78 |
| 收盘价格 | 19.69 |
| 成交量 | 505,292 |
| 平均成交量 (3个月) | 930,591 |
| 市值 | 2,063,104,640 |
| 价格/销量 (P/S) | 3.52 |
| 股市价格/股市净资产 (P/B) | 6.04 |
| 52周波幅 | |
| 利润日期 | 27 Feb 2025 |
| 营业毛利率 | -27.86% |
| 营业利益率 (TTM) | -38.66% |
| 稀释每股收益 (EPS TTM) | -1.56 |
| 季度收入增长率 (YOY) | 20.50% |
| 总债务/股东权益 (D/E MRQ) | 189.72% |
| 流动比率 (MRQ) | 1.46 |
| 营业现金流 (OCF TTM) | -26.37 M |
| 杠杆自由现金流 (LFCF TTM) | 9.29 M |
| 资产报酬率 (ROA TTM) | -8.77% |
| 股东权益报酬率 (ROE TTM) | -46.67% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | NovoCure Limited | 混合的 | 看涨 |
AIStockmoo 评分
0.6
| 分析师共识 | 2.5 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.63 |
|
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Core |
| 内部持股比例 | 9.78% |
| 机构持股比例 | 84.86% |
| 52周波幅 | ||
| 中 | 38.00 (102.45%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 14 Jan 2025 | 38.00 (102.45%) | 购买 | 26.23 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合